Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and
collaborative drug discovery efforts took place in academia and industry, culminating in …

We assessed the in vitro antiviral activity of remdesivir and its parent nucleoside GS-441524,
molnupiravir and its parent nucleoside EIDD-1931 and the viral protease inhibitor …

There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer
developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …

Can SARS-CoV-2 hitchhike on the olfactory projection and take a direct and short route from
the nose into the brain? We reasoned that the neurotropic or neuroinvasive capacity of the …

Rapid changes in the viral genome allow viruses to evade threats posed by the host immune
response or antiviral drugs, and can lead to viral persistence in the host cells. RNA …

Genetic variation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
resulted in the emergence and rapid spread of multiple variants throughout the pandemic, of …

As new pathogens emerge, new challenges must be faced. This is no different in infectious
disease research, where identifying the best tools available in laboratories to conduct an …

In this era, broad‐spectrum prodrugs with anti‐severe acute respiratory syndrome
coronavirus 2 (SARS‐CoV‐2) activities are gaining considerable attention owing to their …